The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutics Development Initiative -- Academic Track, 2008Identification of a novel calcium selective antagonist for neuroprotection in PD
Objective/Rationale:
The objective of the project is to identify a selective and potent antagonist for the Cav1.3 L-type calcium channel. These channels are thought to be responsible for the selective... -
Therapeutics Development Initiative -- Academic Track, 2008Structural and Chemical Approaches to Understand and Modulate LRRK2 Kinase Activity in Parkinson's Disease
Objective/Rationale:
Mutations in LRRK2 cause the most common familial forms, and some sporadic forms, of Parkinson’s disease. Considerable evidence indicates that the neurotoxicity of these LRRK2... -
Critical Challenges in PD: Alpha-synuclein Neuroimaging, 2008Generation of Alpha-Synuclein Conformation Specific Aptamers for In Vivo Bioimaging of Alpha-Synuclein Pathology
Objective/Rationale:
Alpha-synuclein is an abundant brain protein, whose misfolding has been associated to the development of Parkinson’s disease. Visualization of the different misfolded forms of... -
Alpha-Synuclein Imaging, 2008In Vivo SPECT Imaging of Alpha-Synuclein Aggregation with Morphology Specific Antibody Based Ligands
Objective/Rationale:
The protein alpha-synuclein is a major constituent of the Lewy Body aggregates that are a hallmark feature of Parkinson’s disease and has been strongly correlated with the disease... -
Rapid Response Innovation Awards, 2008The Glucosylceramide Pathway in Parkinson's Disease and other Synucleinopathies: Genetic defects, Neuropathological characterization and cell culture models
Objective/Rationale:
Mutations in the beta glucocerebrosidase (GBA) gene are associated with Parkinson’s disease. Only a small number of neuropathologically confirmed PD, multiple system atrophy (MSA)... -
Rapid Response Innovation Awards, 2008Neuronal Nicotinic Acetylcholine Receptor Upregulation for the Treatment of Parkinson's Disease
Objective/Rationale:
Many studies demonstrate an inverse correlation between tobacco use and the risk of Parkinson’s disease. This inadvertent therapeutic effect of tobacco may be caused by the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.